Virtual Press Room

The Virtual Press Room is a courtesy for corporate and institutional public relations professionals. Publication of material on this page does not constitute an endorsement by ASCO of any product or claim.

For information about how to submit a press release to the Virtual Press Room, visit the For PR Professionals page.

2015 ASCO Annual Meeting

Argos Therapeutics
Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial

Boehringer Ingelheim
Boehringer Ingelheim Showcases Expanding Presence in Lung Cancer at ASCO 2015 With New Data Including Presentation of Afatinib Overall Survival Results for Squamous Cell Carcinoma of the Lung

Eisai to Present New Data on Several Oncology Compounds at ASCO 2015 

Fox Chase Cancer Center
African Americans Prone To Display Negative Perceptions of Cancer-Related Clinical Trials
New Targeted Treatment IMMU-130 Shows Promise in Patients with Metastatic Colon Cancer
Next Generation Sequencing-Based Tumor Genomic Profiling Aids in Detecting Hereditary Variants in Cancer Risk Genes
Patient Interest, Willingness to Pay Out of Pocket Costs for Tumor Genetic Profiling Assessed by Fox Chase Researchers

Invitae and Collaborators to Present New Data at the 2015 American Society of Clinical Oncology Annual Meeting Focusing on the Clinical Utility of Multi-Gene Panel Tests for Hereditary Breast and Ovarian Cancer

Ipsen Biopharmaceuticals
Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting 

Myriad Genetics
Myriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting

Real Endpoints
Real Endpoints’ Interactive Model Compares the Value of Different Drug Regimens in HER2+, ER-/PR- Breast Cancer